AI-powered biomedical data harmonization platform for drug discovery
Elucidata builds a data harmonization platform (Polly) that converts raw biomedical datasets into machine-learning-ready formats for pharma and biotech R&D teams. The stack centers on Python, SQL, AWS, and LLM tooling (LangChain, LlamaIndex, AutoGen, Pinecone, Milvus), with active engineering focus on agentic orchestration, RAG pipelines, and LLM cost optimization — indicating a shift toward autonomous AI workflows over manual curation. Leadership-tier hiring in engineering suggests architectural scaling as demand from their 35+ biopharma customer base grows.
Notable leadership hires: Tech Lead
Elucidata operates a data harmonization and curation platform serving early-stage drug discovery, precision diagnostics, and translational biomarker teams at mid-to-large pharma companies and biotech labs. The platform ingests multi-modal biomedical data (genomics, assays, clinical records, real-world data) and applies ML-ready transformation, human-in-the-loop annotation, and QA pipelines to achieve 99.99% data accuracy. Founded in 2015 and based in San Francisco with engineering presence in India, the company raised Series A funding in September 2022. Their customer base includes over 35 biopharma organizations working on use cases ranging from patient stratification to target identification and biomarker discovery.
Core stack: Python, SQL, AWS, Docker. AI/ML: LangChain, LlamaIndex, AutoGen, Pinecone, Milvus. Frontend: React, Angular, HTML, CSS, JavaScript.
120+ multi-disciplinary team members based across the United States and India.
Other companies in the same industry, closest in size